Coherus BioSciences welcomes Charlie Newton to its Board of Directors

– USA, CA –  Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced the appointment of Charlie Newton to its Board of Directors.

“I warmly welcome Charlie to the Coherus Board of Directors. Charlie is a legendary biotech investment banker and a current Chief Financial Officer, who for nearly three decades has partnered with management teams to strategically build shareholder value,” said Denny Lanfear, CEO of Coherus. “We look forward to working closely with him as we execute on our transformation to become a leading immuno-oncology company.

Charlie Newton will also join the Audit Committee.

About Charlie Newton

Charlie Newton is CFO of Lyell Immunopharma, a NASDAQ-listed biotechnology company. Prior to joining Lyell, he served as MD and Co-Head of Healthcare Investment Banking in the Americas at BofA Securities, MD and Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, and MD and Head of Western Region Healthcare Investment Banking at Morgan Stanley. Mr. Newton advised on approximately $200 billion in mergers and acquisitions and raised nearly $60 billion in capital during his investment banking career.

“Coherus is at an inflection point as the Company executes its strategy to invest cash flows from its commercial product portfolio into the rapidly growing immuno-oncology market,” said Charlie Newton. “I have known and worked with the Coherus management team for almost a decade. I had the great pleasure of working on Coherus’ initial public offering during my investment banking career, and I am thrilled to have the opportunity to join the Coherus team as a board member. I believe there are significant opportunities for the Company to maximize the potential of its commercial portfolio, late-stage pipeline and very promising immuno-oncology strategy.”

Mr. Newton earned his MBA from the Tuck School at Dartmouth College as well as a B.S. in Finance from Miami University.

About Coherus BioSciences

Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved products. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus plans to resubmit a BLA for toripalimab for the treatment of advanced nasopharyngeal carcinoma by mid-summer 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of rare and highly prevalent cancers.

Coherus markets UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY (adalimumab-aqvh) in the United States in 2023. The FDA is currently reviewing the biologics license application for CIMERLI (ranibizumab-ranq), a biosimilar of Lucentis, with a target action date of August 2022.

For more information : https://www.coherus.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team